
Rick A Vreman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3389767/publications.pdf Version: 2024-02-01



RICK A VDEMAN

#	Article	IF	CITATIONS
1	Understanding innovation of health technology assessment methods: the IHTAM framework. International Journal of Technology Assessment in Health Care, 2022, 38, e16.	0.2	2
2	Addressing uncertainty in relative effectiveness assessments by HTA organizations. International Journal of Technology Assessment in Health Care, 2022, 38, e17.	0.2	3
3	Real World Data in Health Technology Assessment of Complex Health Technologies. Frontiers in Pharmacology, 2022, 13, 837302.	1.6	15
4	Reported Challenges in Health Technology Assessment of Complex Health Technologies. Value in Health, 2022, 25, 992-1001.	0.1	9
5	Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 9, 76-84.	1.4	3
6	Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. Value in Health, 2021, 24, 121-128.	0.1	6
7	Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. International Journal of Technology Assessment in Health Care, 2021, 37, e83.	0.2	10
8	Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decisionâ€making of oncology medicines. Pharmacology Research and Perspectives, 2021, 9, e00742.	1.1	9
9	Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clinical and Translational Science, 2021, 14, 1566-1577.	1.5	10
10	Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. Value in Health, 2021, 24, 759-769.	0.1	24
11	Comment on "Deterministic Sensitivity Analysis Under Ignorance― Pharmacoeconomics, 2021, 39, 1199-1199.	1.7	0
12	The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. Pharmacoeconomics, 2021, 39, 1-17.	1.7	21
13	Getting the Right Evidence After Drug Approval. Frontiers in Pharmacology, 2020, 11, 569535.	1.6	10
14	Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. International Journal of Environmental Research and Public Health, 2020, 17, 8309.	1.2	20
15	Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. Drug Discovery Today, 2020, 25, 1223-1231.	3.2	11
16	Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 2020, 108, 350-357.	2.3	41
17	A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics. European Journal of Health Economics, 2020, 21, 845-853.	1.4	1
18	Efficacy gap between phase II and subsequent phase III studies in oncology. British Journal of Clinical Pharmacology, 2020, 86, 1306-1313.	1.1	8

RICK A VREMAN

#	Article	IF	CITATIONS
19	Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations. Value in Health, 2020, 23, 10-16.	0.1	37
20	Increasing the information provided by probabilistic sensitivity analysis: The relative density plot. Cost Effectiveness and Resource Allocation, 2020, 18, 54.	0.6	2
21	The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International Journal of Health Policy and Management, 2020, , .	0.5	8
22	Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied Health Economics and Health Policy, 2019, 17, 883-893.	1.0	15
23	Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions. Value in Health, 2019, 22, 1275-1282.	0.1	65
24	Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs. Clinical Pharmacology and Therapeutics, 2019, 105, 684-691.	2.3	34
25	Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. Pharmacogenomics, 2017, 18, 1143-1153.	0.6	5